SPL801B

SPL801B is a **preclinical oral small-molecule neuropsychiatric drug candidate** developed by **Small Pharma** for depressive disorders, including **major depressive disorder**. It is an optimized oral formulation of **2R,6R-hydroxynorketamine**, an active metabolite of ketamine, being investigated for **rapid antidepressant effects** while potentially avoiding the dissociative and psychoactive liabilities associated with ketamine itself. The precise therapeutic target and mechanism have not been fully established publicly, but the program is positioned as a non-ketamine-acting antidepressant approach derived from ketamine metabolism and protected by patents covering use alone and in combination with serotonin modulators.

Other names

2R,6R-hydroxynorketamine6-HNK2R,6R-HNK